GC Biotherapeutics Inc. (GCBT) is a newly established biopharmaceutical company in Montreal, Canada, and the North American headquarters of GC (formerly known as Green Cross), a global Healthcare and Biotechnology company based in South Korea. Reinforced with over half-century experience in delivering biotherapeutics and healthcare solutions worldwide, we have recently completed the installation of the first and only commercial-scale plasma fractionation facility in Canada. Our biotechnologies to manufacture plasma derivatives will ensure security and access to difficult to make but necessary biotherapies.
Since 1967, GC specializes in the development and commercialization of plasma derivatives, preventative vaccines, recombinant proteins, and therapeutic antibodies. As the first producers of plasma-derived therapeutics in South Korea, GC has acquired unparalleled expertise and over five decades of helping patients with infectious or immune diseases lead healthier lives.
GC has been ceaselessly pursuing its mission with single-mindedness toward becoming a global health industry leader. GC is now ready to join the ranks of the global health industry, as an active member in research, development, and provision of a broad array of pharmaceutical products, medical devices, and healthcare services for better global prevention, diagnosis, and treatment of diseases of the body and mind.